Physician profile
Robert A Mackin
NPI 1447334784
$1,648.36
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $391 · 2021: $444.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,264.93 | 2019-2021 | |
| Amarin Pharma, INC. | $198.94 | 2019-2021 | |
| Amgen INC. | $72.63 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $20.93 | 2021 | |
| Pfizer INC. | $20.66 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.48 | 2019 | |
| Merck Sharp & Dohme LLC | $13.69 | 2021 | |
| Abbott Laboratories | $13.40 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.25 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$130,519.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mackin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.